TNFRSF17 and neoplasm: Furthermore, multiple cases of patient relapse involving tumor cells with downregulated BCMA expression have been reported4,5,7, underscoring antigen escape as a significant obstacle in the treatment of MM with BCMA CAR-T cell therapy.